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Lissencephaly is a type of the congenital malformation of the brain.
Due to the impairments of neuronal migration, patients show
absence of brain convolution manifesting smooth brain surfaces.
One of the human genes responsible for lissencephaly is the
platelet-activating factor acetylhydrolase 1b gene (PAFAH1B; also
known as LIS1) located on 17p13.3. Patients with heterozygous
deletion of this chromosomal region exhibit lissencephaly. Recently,
we encountered a male patient who showed typical lissencephaly.
Using a microarray analysis, we identiﬁed a 1.3 Mb submicroscopic
deletion in 17p13.3. This deletion included PAFAH1B. Both of the
parents showed no deletion in this region. Therefore, this was
determined to be derived from de novo origin. After obtaining the
written informed consent, skin ﬁbroblasts were provided from this
patient and disease-speciﬁc induced pluripotent stem (iPS) cells
were generated and used for medical research (Shimojima K,
Okumura A, Hayashi M, Kondo T, Inoue H, and Yamamoto T.
CHCHD2 is down-regulated in neuronal cells differentiated from iPS
cells derived from patients with lissencephaly. Genomics, in press).
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).ier Inc. This is an open access article under the CC BY license
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More speciﬁc
subject areaGenomicsType of data Patient descriptions and resulted data analyzed by microarray-based comparative genomic
hybridization (CGH) analysis and ﬂuorescence in-situ hybridization (FISH) analysisHow data was
acquiredUsing Agilent SureScan Microarray Scanner, Agilent Genomic Workbench software, and Leica
CTR6000Data format Descriptions of a patient and captured ﬁgures by equipments
Experimental factors Clinical information and biological samples from a patient who exhibited lissencephaly
Experimental
featuresUsing microarray-based comparative genomic hybridization (CGH) analysis and ﬂuorescence in-situ
hybridization (FISH) analysis, genomic copy number aberration was analyzed in a patient who
exhibited lissencephaly.Data source location Tokyo Women's Medical University Institute for Integrated Medical Sciences (TIIMS), Tokyo, Japan
Data accessibility These data are with this article.Value of the data A 3-year-old boy showed epileptic spasms at 4 months.
 Brain magnetic resonance imaging (MRI) demonstrated lissencephaly in this patient.
 Microarray-based comparative genomic hybridization (CGH) analysis identiﬁed a 1.3 Mb deletion
in 17p13.3 region, in which PAFAH1B is located.
 Fluorescence in-situ hybridization (FISH) analysis conﬁrmed a deletion in the patient but not in his
parents, indicating de novo origin.
Data, experimental design, materials and methods
Clinical information
A 3-year-old boy was born after 40 weeks of gestation with a birth weight of 3270 g. He was the
ﬁrst product of non-consanguineous healthy parents. There was no family history of neurological
disorders. His perinatal history was unremarkable, whereas a paucity of social smile and eye following
was noticed at his 3-month health check-up.
He had had clusters of epileptic spasms after 4 months of age. Within a week, the frequency of
epileptic spasms increased to several clusters per day and he was admitted to our hospital. On
admission, neurological examinations showed mild hypotonia of the trunk and the extremities with
normal reﬂexes. There was no dysmorphic features. Electroencephalogram (EEG) showed hypsar-
rhythmia associated with high voltage theta activities, predominant in the bilateral temporo–parieto–
occipital regions. Brain magnetic resonance imaging (MRI) demonstrated lissencephaly with agyria in
the parieto–occipital regions and pachygyria in the fronto–central regions (Fig. 1).
He was treated with ACTH therapy. Although the epileptic spasms were markedly reduced by ACTH,
complete seizure cessation was not achieved. Valproate and clobazam were administered after ACTH
therapy and his seizures were controlled transiently. However, a recurrence of epileptic spasms occurred
2 weeks later. ACTH therapy was performed again at 7 months of age and epileptic spasms were completely
controlled. After 12 months of age, he had seizures associated with asymmetric fencing-like posture lasting
for 10 s. Ictal EEG revealed focal rhythmic fast activities in the bilateral frontal regions, thus his seizures were
judged to be focal. Valproate, clobazam, topiramate, and levetiracetam were administered, but these drugs
were not effective. He had 30–50 focal seizures every day. In addition, epileptic spasms also recurred after 18
months of age. At 21 months of age, ACTH therapy was again performed in combination with the
administration of high dose phenobarbital. Epileptic spasms were eliminated and focal seizures were
markedly reduced to 2–3 seizures per week.
At the last follow-up at 44 months of age, he had a few focal seizures per week and no epileptic spasms
under treatment with phenobarbital and topiramate. However, his psychomotor development was severely
delayed. No head control had achieved and verbal communication remained impossible.
Fig. 1. Brain magnetic resonance images of the patient examined at 5 months. T1- (left) and T2- (right) weighted axial images
show volume loss and hypomorphic convolution of the brain cortex.
Fig. 2. The result of chromosomal microarray testing. Schematic representation of chromosome 17 visualized by Chromosome
View of Agilent Workbench (left; Agilent Technologies) shows an aberration at 17p13.2-p13.3, which is expanded by Gene View
(right). PAFAH1B (LIS1) is included in the aberration region (a red circle).
K. Shimojima et al. / Data in Brief 4 (2015) 488–491490Conventional chromosomal analysis showed a normal male karyotype of 46,XY.
Molecular cytogenetic diagnosis
Chromosomal microarray testing using Agilent Human Genome microarray 60 K (Agilent
Technologies, Santa Clara, CA) was performed according to the method described previously [1,2].
Using QIAamp DNA extraction kit (Qiagen, Hilden, Germany), genomic DNA was extracted from blood
samples obtained with written informed consent, following approval by the ethical committee of our
institution. The result showed an aberration with a 1.3 Mb width and a mean log2 ratio of –1.086387,
indicating arr 17p13.3p13.2(2,371,080–3,686,008)1 (Fig. 2), according to build19.
Then, ﬂuorescence in-situ hybridization (FISH) analysis was performed to conﬁrm the result of
chromosomal microarray testing, using human bacterial artiﬁcial chromosomes (BAC) as the probes;
CTD-2576K4 (chr17p13.3:2,492,176–2,643,505) as a target and RP11-1D5 (chr17p13.1:7,918,567–
8,082,208) as a marker referring build19, which were selected from the UCSC genome browser (http://
www.gwenome.ucsc.edu)(GRCh37/hg19). Metaphase spreads prepared from peripheral blood
lymphocytes by using standard methods were used as described previously [1,2]. Finally, a single
signal of the target was identiﬁed, indicating a heterozygous deletion in this patient (Fig. 3). Because
both of the parents did not show any signal deletion, de novo origin was determined in this case.
Fig. 3. The result of FISH. A single green signal labeled for CTD-2576K4 indicates a deletion of this region. Two red signals
labeled for RP11-1D5 are the marker of chromosome 17.
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